NEW YORK (GenomeWeb) – Nemucore and the Medical Prognosis Institute (MPI) announced today that they have partnered to identify potential responder patients for enrollment in a clinical trial of an undisclosed Nemucore cancer therapeutic.

Under the deal, Nemucore will use MPI's Drug Response Predictor Biomarker platform — which is used to develop tumor-derived gene signatures that may be predictive of how patients respond to certain oncology treatment — to potentially select participants for a planned Phase IIb study of one of its cancer drug candidates.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Researchers have treated an X-linked genetic disease affecting three babies in utero, Stat News reports.

The Associated Press reports that the US Centers for Disease Control and Prevention is beefing up sequencing as a tool to investigate foodborne illnesses.

Researchers have sequenced samples from ancient toilets to study past eating habits and health, NPR reports.

In Nature this week: ash dieback disease fungal genome, and more.